Abstract: Thousands of variant gene sequences of SARS-CoV-2 have been emerged since the COVID-19 epidemic broke out in Dec. 2019. Alpha (B. 1.1. 7), Beta (B. 1.351), Gamma (P. 1), Delta (B. 1.617.2) and Omicron (B. 1.1. 529) were the most representative variants. With the continuous emergence of new variants, the predominant strain in the global pandemic as of Jan. 2025 is the Omicron BA.2.86-derived mutant, JN.1. The effectiveness of drugs against Omicron variants remains a key research focus in the treatment of SARS-CoV-2 infections. The infectiousness and pathogenicity of the variants altered remarkably due to mutations in the genome on S protein of the mutant strains, and these emerging variants are more likely to evade immunity and were more infectious than the previous prevalent variants. During the process of combating with the constantly emerging novel variants, drugs showed various effects on treatment of diseases caused by different variants. New drugs and treatment countermeasures are constantly updated with the prevalence of various variants. The current status of research on present drugs for treatment of SARS-CoV-2 and the therapeutic effects on emerging variants are reviewed in the article so as to provide reference for prevention and treatment of the upcoming evolved variants.